oral Hsp90 inhibitor IPI-493

Definition / meaning of oral Hsp90 inhibitor IPI-493

An orally bioavailable formulation of the ansamycin derivative 17-amino-17-demethoxygeldanamycin (17-AG) with potential antineoplastic activity. Oral Hsp90 inhibitor IPI-493 binds to and inhibits Hsp90, which may result the in growth inhibition in sensitive tumor cell populations. Hsp90, a 90 kDa molecular chaperone, may be highly expressed in tumor cells, playing a key role in the conformational maturation, stability and function of other substrate or “client” proteins within the cell; many of these client proteins are involved in signal transduction, cell cycle regulation and apoptosis, and may include kinases, transcription factors and hormone receptors.

Listed under:

Find More About 'oral Hsp90 inhibitor IPI-493'


The Web site of the National Cancer Institute (http://www.cancer.gov/)

Leave a Comment


This site uses Akismet to reduce spam. Learn how your comment data is processed.